Bayer To Market Alza Viadur In U.S.; Weighs International Agreement
Bayer is considering an international marketing arrangement for Alza's Viadur following an agreement to market the long-acting leuprolide acetate implant for prostate cancer in the U.S.
You may also be interested in...
Alza is considering whether to find a marketing partner for Viadur in anticipation of a late 2000/early 2001 launch for the long-acting implant for palliative treatment of advanced prostate cancer.
Abbott and Alza are discussing whether the five-year copromotion agreement for Alza's Ditropan XL (oxybutynin) will survive the Dec. 16 collapse of the pending merger.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011